A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Phase 1/2
47
about 2.3 years
18+
1 site in FL
What this study is about
Researchers are testing the safety and efficacy of LB-100, a medication, for patients with low or intermediate-1 risk myelodysplastic syndromes. The trial will involve administering LB-100 intravenously over 120 minutes in two phases: an escalating dose phase to determine a safe dose and a dose-finding phase to assess the drug's efficacy and safety.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LB-100
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: For Phase 2 - Best overall response rate of patients to the study treatment as a measure of efficacy of LB-100 study drug, For Phase Ib - Number of patients with adverse events related to the study treatment as a measure of safety and tolerability of LB-100 study drug